SRRM2-AS1: A Promising Drug Target and Biomarker (G100128788)

Target Name: SRRM2-AS1

NCBI ID: G100128788

SRRM2-AS1

Other Name(s): SRRM2 antisense RNA 1 | SRRM2 antisense RNA 1, transcript variant 1

SRRM2-AS1: A Promising Drug Target and Biomarker

The identification and characterization of drug targets and biomarkers have significantly transformed the field of medicine, enabling the development of more effective therapies and precise diagnostic tools. One such potential drug target and biomarker is SRRM2-AS1. In this article, we will explore the role and significance of SRRM2-AS1, shedding light on its potential for therapeutic intervention and as a marker for various diseases.

Understanding SRRM2-AS1
SRRM2-AS1, short for serine and arginine-rich splicing factor 2 antisense RNA 1, is a long non-coding RNA (lncRNA) located on human chromosome 1. lncRNAs are RNA molecules with a length greater than 200 nucleotides that lack protein-coding potential. While initially considered as "transcriptional noise," extensive research has revealed their crucial roles in various biological processes and diseases.

The Function of SRRM2-AS1
Through its interaction with different cellular components, SRRM2-AS1 exerts regulatory effects on gene expression and protein function. Emerging evidence suggests that SRRM2-AS1 predominantly functions as a modulator of RNA splicing, a process crucial for generating functionally diverse proteins from a single gene.

Researchers have demonstrated that SRRM2-AS1 associates with serine and arginine-rich splicing factors (SRSFs) to guide their binding to pre-mRNA molecules. This interaction influences alternative splicing events, where different combinations of exons are included or excluded, resulting in the production of distinct protein isoforms. Dysregulation of alternative splicing has been linked to numerous diseases, including cancer, neurological disorders, and cardiovascular conditions.

SRRM2-AS1 as a Drug Target
The aberrant expression of SRRM2-AS1 has been observed in various diseases, making it an attractive target for therapeutic intervention. Studies have revealed its potential role in cancer progression and metastasis. For instance, in ovarian cancer, increased expression of SRRM2-AS1 has been associated with tumor growth, invasion, and drug resistance. By targeting SRRM2-AS1, researchers hope to disrupt its splicing regulatory function and inhibit cancer cell growth.

Furthermore, SRRM2-AS1 has been implicated in neurological disorders such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In Alzheimer's disease, it has been observed that SRRM2-AS1 interacts with RNA binding proteins, leading to abnormal splicing of genes implicated in neuronal function and survival. Targeting SRRM2-AS1 could potentially restore normal splicing patterns, offering a novel therapeutic approach for neurodegenerative diseases.

SRRM2-AS1 as a Biomarker
In addition to its potential as a drug target, SRRM2-AS1 has shown promise as a diagnostic biomarker for various diseases. Its dysregulated expression levels can be detected in body fluids such as blood, saliva, and urine, making it a non-invasive and easily assessable marker.

In cancer, elevated SRRM2-AS1 levels have been correlated with poor patient prognosis, suggesting its potential as a prognostic biomarker. Moreover, its presence in liquid biopsies could facilitate early detection and monitoring of cancer progression or response to treatment. This can greatly contribute to personalized medicine, allowing clinicians to tailor therapy based on individual molecular profiles.

In neurological disorders, abnormal expression of SRRM2-AS1 has been observed in patient samples, highlighting its potential as a diagnostic biomarker. Its detection in cerebrospinal fluid or blood samples could aid in early disease detection and monitoring, enabling timely interventions and improving patient outcomes.

Conclusion
SRRM2-AS1 is emerging as a significant player in the world of medicine. Its function as a modulator of RNA splicing presents opportunities for therapeutic targeting in cancer and neurological disorders. Additionally, its dysregulated expression makes it a valuable biomarker for diagnosis, prognosis, and monitoring disease progression. Ongoing research efforts hold the promise of uncovering the precise molecular mechanisms underlying SRRM2-AS1's roles and establishing its potential as a drug target and biomarker in various diseases.

Protein Name: SRRM2 Antisense RNA 1

The "SRRM2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRRM2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets